Zum Inhalt springen

First smart automated artificial urinary sphincter (AUS)

UroMems, a global company developing innovative, mechatronics technology to treat stress urinary incontinence (SUI), announced today that it has successfully met the six-month primary endpoint for the first-ever female patient implanted with the UroActive™ System, the first smart automated artificial urinary sphincter (AUS) to treat SUI. This milestone indicates a new era for millions of women suffering from SUI, and signals an exciting transition for surgeons treating SUI not only in France, where the female patient was treated, but also across Europe and the U.S. It also follows closely on the heels of the successful results of the complete treatment cohort of the first-in-man clinical feasibility study. Results of this clinical study will contribute to the design and implementation of UroMems‘ pivotal clinical trial in Europe and the U.S.

AusperBio Announces Major Progress in AHB-137 Clinical Development

AHB-137, empowered by AusperBio’s proprietary Med-OligoTM ASO technology platform, holds the potential as a backbone in the quest for a functional cure for CHB. This novel dual-mechanism ASO has been evaluated in two Phase 1a/1b clinical trials in parallel, one in China and another outside China. To date, 122 participants, including 30 CHB patients, have received either single or multiple doses of AHB-137. In China (chinadrugtrials.org.cn #CTR20232098; clinicaltrials.gov #NCT06115993), enrollment of CHB patients in the 150mg and 300mg cohorts has been completed. The study outside China (clinicaltrials.gov #NCT05717686) is also rapidly progressing in dosing of CHB patients, with 6 participants having completed 4-week dosing in the US and New Zealand. About Chronic Hepatitis B Chronic Hepatitis B (CHB) infection is a liver disease estimated to affect nearly 290 million people worldwide and is a leading cause of major liver diseases… 

more »AusperBio Announces Major Progress in AHB-137 Clinical Development

Deutsche misstrauen dem Gesundheitswesen

Die Zufriedenheit der Deutschen mit dem Gesundheitswesen ist auf einen Tiefstand gesunken, wie eine neue Studie der Wirtschaftsprüfungsgesellschaft PwC aufzeigt. Das berichtet die Pharmazeutische Zeitung. „Fast zwei Drittel der Bundesbürger sorgen sich um die Verfügbarkeit ihrer Medikamente in der Apotheke“, so das Blatt. https://www.pharmazeutische-zeitung.de/vertrauen-der-deutschen-in-gesundheitswesen-schwindet-145491/

an artificial intelligence illustration on the wall

BREAKING: KI lässt sich nicht beherrschen

  • KI

Laut einer umfassenden Untersuchung gibt es derzeit keine Beweise dafür, dass KI sicher kontrolliert werden kann, und ohne den Nachweis, dass KI kontrolliert werden kann, sollte sie nicht entwickelt werden, warnt ein Forscher.

CRISPR-Kopien: Neues Werkzeug beschleunigt und optimiert Genom-Editierung

CRISPR/Cas-Systeme haben im letzten Jahrzehnt enorme Fortschritte gemacht. Diese präzisen Genom-Editierwerkzeuge finden Anwendung in der Entwicklung transgener Pflanzen bis hin zur Gentherapie und darüber hinaus. Und mit ihrer jüngsten Entwicklung von CRISPR-COPIES verbessern die Forscher des Center for Advanced Bioenergy and Bioproducts Innovation (CABBI) die Vielseitigkeit und Benutzerfreundlichkeit von CRISPR weiter.

Targeted DNA Methylation Sequencing Service

Wasatch Biolabs (WBL), a subsidiary of Renew Biotechnologies and a certified Oxford Nanopore Technologies‘ laboratory, launches a proprietary Targeted DNA Methylation Sequencing Service for researchers and clinical service providers. The technique is amplification and bisulfite conversion free, effectively bypassing the most common limitations of targeted methylation analysis and enabling WBL to create custom methylation panels that target an unprecedented hundreds-to-thousands of genomic loci of interest with an enrichment of 400-2300x Clinical applications have historically been hindered by available methods to analyze DNA methylation. Bisulfite sequencing, which involves chemical treatment of DNA with sodium bisulfite and PCR amplification, remains the de facto standard for DNA methylation analysis. However, bisulfite conversion is known to damage DNA, and amplification is prone to errors and biases. Because of these limitations, WBL has developed a targeted sequencing protocol that is bisulfite and PCR amplification free.… 

more »Targeted DNA Methylation Sequencing Service

New Assay Identifies Clinically Relevant Gene Fusions in Pediatric Tumors

Researchers at Children’s Hospital Los Angeles report in The Journal of Molecular Diagnostics about a new tool that effectively integrates data from four fusion callers and identifies disease-related gene fusions Philadelphia, February 13, 2024 – Identification of specific gene fusions is critical for the successful targeted treatment of pediatric cancer patients. Researchers at Children’s Hospital Los Angeles have developed a novel assay that automatically integrates the data from multiple fusion identification tools (callers) and efficiently and accurately identifies clinically relevant gene fusions in pediatric tumors. Their results are reported in The Journal of Molecular Diagnostics, published by Elsevier. An Exome Capture-Based RNA-Sequencing Assay for Genome-Wide Identification and Prioritization of Clinically Important Fusions in Pediatric Tumors,” by Jonathan Buckley, Ryan J. Schmidt, Dejerianne Ostrow, Dennis Maglinte, Moiz Bootwalla, David Ruble, Ananthanarayanan Govindarajan, Jianling Ji, Alexandra E. Kovach, Etan Orgel, Gordana Raca, Fariba Navid, Leo Mascarenhas, Bruce Pawel,… 

more »New Assay Identifies Clinically Relevant Gene Fusions in Pediatric Tumors

New mechanism could improve the efficiency of diabetes treatments

The study, published in the journal Metabolism, focuses on the GDF15 protein, a factor that is expressed at high levels in many diseases, such as heart failure, cancer and fatty liver disease. Obese patients also have elevated levels of this protein, but its function is altered and those affected may develop resistance to GDF15 — that is, a reduction in the effectiveness of its activity. The study is led by Professor Manuel Vázquez-Carrera, from the Faculty of Pharmacy and Food Sciences of the UB, the Institute of Biomedicine of the UB (IBUB), the Sant Joan de Déu Research Institute (IRSJD) and CIBERDEM. The study also highlights the participation of researchers Patricia Rada and Ángela María Valverde, also collaborators at CIBERDEM, the Spanish National Research Council (CSIC) and the Autonomous University of Madrid (UAM). The work has the collaboration of Professor… 

more »New mechanism could improve the efficiency of diabetes treatments

Premiere: Erstes unterirdisches Laboratorium in Afrika

Das erste unterirdische Wissenschaftslabor Afrikas könnte in den nächsten fünf bis zehn Jahren Realität werden: das Paarl Africa Underground Laboratory (PAUL) in den Du Toits Kloof-Bergen am Westkap in Südafrika, das über den bestehenden Hugenottentunnel erreichbar ist.